Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1884 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare two different follow up regimens with different test intensity in endometrial cancer treated patients.

If eligibility criteria are satisfied and the written informed consensus is obtained, patients are stratified inside the centre according to their risk level:

* Group 1 : patients at low risk of recurrence \[stage IA G1 and stage IA G2\]
* Group 2 : patients at high-risk of recurrence \[≥ stage IA G3\] (Ethics Committee amendment of 14th September 2010, use new 2010 FIGO classification for endometrial cancer!)

In each group patients will be randomized in two regimens of follow up:

1. Minimalist (Arm 1)
2. Intensive (Arm 2)

Features of each arm are listed in "Arms" item.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endometrial Changes in Breast Cancer Women.

NCT05717634

Endometrial Cancer Endometrial Hyperplasia With Atypia Breast Cancer +1 more

UNKNOWN

Sentinel Node and Endometrial Cancer

NCT00987051

Endometrial Neoplasms

COMPLETED NA

Telephone Follow-up After Treatment for Endometrial Cancer

NCT01610375

Endometrial Cancer

COMPLETED NA

Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia

NCT04756713

Gestational Trophoblastic Neoplasia Molar Pregnancy Gestational Trophoblastic Tumor, Non-Metastatic

RECRUITING PHASE3

Sentinel Node in Endometrial Cancer

NCT04492995

Endometrial Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The procedure for centralized randomization, with blocks of variable length, will take place within each layer with 1:1 ratio and will be implemented within the centralized database, with sequences generated by dedicated software. The recruitment and randomization has to be registered on the website (www.epiclin.cpo.it) no later than 20 days after histological examination has been received. If patients do not need any kind of adjuvant therapy they will start follow-up program according to the regimen chosen for them at randomization, if adjuvant therapy is needed the patient at first will be registered and the randomization will be deferred at the end of treatment.

In presence of symptoms or signs detected during the clinical visit which may suppose a recurrence or in presence of abnormal tests, the clinician has to prescribe all medical tests and examinations required. The tests carried out in addition to follow-up scheduled program must be reported in the database. Nevertheless patients continue to be followed for the assessment of the performance status at 5 years, but the follow-up schedule is up to the clinician. An interim analysis is scheduled in 3.5 years starting from the beginning of recruitment (based on approximately 1 / 3 of the total expected events, when about 4 / 5 cases have already been enrolled). Patients will be stratified by recruitment Center, by level of risk (calculated according to the stage of the disease, the histotype and the grading) and by type of treatment performed.

The focus of the study is to:

* Compare the effect of two FU regimens on 5-years OS
* Evaluate the difference in diagnosis anticipation
* Evaluate the difference in terms of recurrences
* Describe the compliance and QoL of patients
* Evaluate the cost-effectiveness and the cost-utility

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intensive follow up

Intensive follow up in low-risk patients Intensive follow up in high-risk patients

Group Type EXPERIMENTAL

Intensive/Low-Risk follow up (IA G1; IA G2)

Intervention Type PROCEDURE

\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months

\- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months

\* clinical visit with gynecological exploration

Intensive/High-Risk follow up (≥ IA G3)

Intervention Type PROCEDURE

\- First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months

\- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months

\* clinical visit with gynecological exploration

Minimalist follow up

Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients

Group Type EXPERIMENTAL

Minimalist/Low-Risk follow up (IA G1; IA G2)

Intervention Type PROCEDURE

\- First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.

\* clinical visit with gynecological exploration

Minimalist/High-Risk follow up (≥ IA G3)

Intervention Type PROCEDURE

\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months

\- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.

\* clinical visit with gynecological exploration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intensive/Low-Risk follow up (IA G1; IA G2)

\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months

\- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months

\* clinical visit with gynecological exploration

Intervention Type PROCEDURE

Intensive/High-Risk follow up (≥ IA G3)

\- First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months

\- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months

\* clinical visit with gynecological exploration

Intervention Type PROCEDURE

Minimalist/Low-Risk follow up (IA G1; IA G2)

\- First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.

\* clinical visit with gynecological exploration

Intervention Type PROCEDURE

Minimalist/High-Risk follow up (≥ IA G3)

\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months

\- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.

\* clinical visit with gynecological exploration

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients treated surgically for endometrial cancer, if in complete clinical remission confirmed by imaging stage FIGO I-IV
* no previous or concurrent neoplasia (with the exception of carcinoma in situ of the cervix and basalioma of the skin)
* other contemporaneous RCT may be allowed if there is not any restriction concerning follow up
* obtaining a written informed consensus before randomization
* age \> 18 years

Exclusion Criteria

* presence of any psychological, familial, sociological or geographical condition that could potentially limit the compliance to the protocol and the follow-up planned: all these situations must be discussed with the patient before the randomization
* previous, concurrent or second malignancies endometrial carcinoma in the context of a hereditary syndrome
* conditions which contraindicate medical tests scheduled according to follow-up regimen

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No